Artivion Wins FDA Green Light for NEXUS Arch Stent, Eyes Endospan Buyout

Artivion, Inc. (NYSE: AORT) has received U.S. FDA approval for the NEXUS Aortic Arch System, the first off‑the‑shelf branched endovascular stent graft specifically designed to treat aortic arch disease, including aneurysms and dissections, in high‑risk patients. NEXUS, already CE‑marked and commercial in Europe since 2019, offers a minimally invasive alternative to complex open‑chest arch surgery, which carries significant morbidity, long hospital stays, and challenging recoveries.

Strong TRIOMPHE data underpins approval

FDA approval is supported by 1‑year results from the TRIOMPHE IDE trial, which enrolled 94 high‑risk patients with chronic arch dissections, aneurysms, or other arch pathology treated with NEXUS. Data showed high survival with low rates of stroke, renal failure requiring dialysis, myocardial infarction, and other major adverse events, and outcomes were consistent with earlier European experience, suggesting a reliable, reproducible off‑the‑shelf solution for complex arch repair.

Triggers 90‑day window to acquire Endospan

NEXUS is developed by privately held Endospan, Artivion’s long‑standing partner; under a 2019 option agreement, FDA approval activates Artivion’s right to acquire Endospan any time within 90 days of the approval notice. Artivion has already amended that deal, lowering the upfront purchase price to 135 million dollars (inclusive of loan offsets) and eliminating a previous 100‑million‑dollar minimum earn‑out, and has lined up a 150‑million‑dollar delayed‑draw term loan to fund a potential acquisition.

Strategic fit with Artivion’s aortic platform

NEXUS would sit alongside Artivion’s AMDS hybrid prosthesis—already granted a U.S. humanitarian device exemption for acute DeBakey type I dissections with malperfusion—to create a differentiated portfolio across the aortic arch continuum. Management views NEXUS and AMDS as key growth drivers in aortic repair, with NEXUS offering a fully endovascular option for chronic arch disease and AMDS remodeling the arch in acute settings, reinforcing Artivion’s positioning as a leader in complex aortic surgery solutions.

Investor angle for AORT

For AORT shareholders, FDA approval of NEXUS is a significant de‑risking event that opens a new U.S. revenue stream and strengthens Artivion’s high‑margin aortic device franchise. The key near‑term swing factor is whether the company exercises its Endospan option and on what timeline; a deal would add integration and leverage risk but also bring NEXUS fully in‑house, potentially expanding Artivion’s addressable market and supporting the company’s long‑term goal of building a billion‑dollar aortic pipeline.